The redox ratio and fluorescence lifetimes of NAD(P)H and FAD were quantified in organoids treated for 1 day with cetuximab, cisplatin, or their combination.

<p>(A) The redox ratio increases with cetuximab treatment and decreases with cisplatin and the combination treatment. (B) The NAD(P)H lifetime decreases with cetuximab, cisplatin, and combination treatment. (C) The FAD lifetime increases with cetuximab, cisplatin, and combination treatment. *p<0.05, t-test; n~50–200 cells per group.